LANDUZZI, LORENA
 Distribuzione geografica
Continente #
NA - Nord America 4.494
AS - Asia 3.615
EU - Europa 3.237
AF - Africa 257
SA - Sud America 172
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.781
Nazione #
US - Stati Uniti d'America 4.421
VN - Vietnam 1.052
CN - Cina 999
SG - Singapore 939
IT - Italia 855
GB - Regno Unito 630
DE - Germania 456
SE - Svezia 288
HK - Hong Kong 286
RU - Federazione Russa 161
IN - India 136
NL - Olanda 131
BR - Brasile 125
FR - Francia 123
CH - Svizzera 122
UA - Ucraina 116
IE - Irlanda 108
CI - Costa d'Avorio 105
TG - Togo 57
KR - Corea 56
CA - Canada 55
ZA - Sudafrica 55
FI - Finlandia 51
EE - Estonia 45
JP - Giappone 44
BG - Bulgaria 39
BE - Belgio 29
ID - Indonesia 28
JO - Giordania 24
PL - Polonia 20
AR - Argentina 17
RO - Romania 14
SC - Seychelles 14
MX - Messico 13
AT - Austria 11
LT - Lituania 11
NG - Nigeria 11
EC - Ecuador 10
TR - Turchia 9
CL - Cile 7
EG - Egitto 7
IR - Iran 7
MA - Marocco 6
CO - Colombia 5
GR - Grecia 5
HR - Croazia 5
IQ - Iraq 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
BD - Bangladesh 4
DK - Danimarca 4
ES - Italia 4
MD - Moldavia 4
AU - Australia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
KG - Kirghizistan 2
PE - Perù 2
PY - Paraguay 2
TW - Taiwan 2
UZ - Uzbekistan 2
VE - Venezuela 2
YE - Yemen 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
HN - Honduras 1
IL - Israele 1
JM - Giamaica 1
KH - Cambogia 1
LB - Libano 1
LI - Liechtenstein 1
LV - Lettonia 1
MK - Macedonia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
SA - Arabia Saudita 1
SN - Senegal 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 11.781
Città #
Singapore 643
Southend 526
Fairfield 511
Ashburn 493
Chandler 481
Hong Kong 285
Ann Arbor 240
Woodbridge 237
Houston 218
Ho Chi Minh City 210
Seattle 208
Wilmington 206
Bologna 198
Dong Ket 198
Hanoi 183
Shanghai 177
Cambridge 166
Hefei 148
Santa Clara 144
Princeton 133
Beijing 114
Bern 112
Dublin 108
Abidjan 105
Boardman 101
Frankfurt am Main 87
Jacksonville 75
Dallas 59
Lomé 57
Seoul 53
Westminster 53
Bremen 52
Nanjing 52
Milan 48
Los Angeles 47
Padova 45
Berlin 43
Tokyo 41
Sofia 39
Guangzhou 35
Helsinki 33
Buffalo 31
San Diego 31
Jinan 30
Shenyang 30
Brussels 28
Saint Petersburg 26
Turin 26
Redondo Beach 25
Amman 24
Des Moines 24
Falkenstein 24
Ottawa 24
Amsterdam 23
Jakarta 23
Redmond 23
Redwood City 23
Casalecchio di Reno 22
London 22
Phoenix 21
Da Nang 20
Hebei 19
Nanchang 19
Changsha 18
New York 18
Hải Dương 17
Biên Hòa 16
Mülheim 16
Ha Long 15
Haiphong 15
Tianjin 15
Toronto 15
Warsaw 14
Bengaluru 13
Can Tho 13
Florence 13
Quận Bình Thạnh 13
Yubileyny 13
Jiaxing 12
Lappeenranta 12
São Paulo 12
Verona 12
Zhengzhou 11
Abeokuta 10
Bühl 10
Nuremberg 10
Bắc Ninh 9
Dearborn 9
Mahé 9
Moscow 9
Parma 9
Bắc Giang 8
Catanzaro 8
Falls Church 8
Kuban 8
Ningbo 8
Ninh Bình 8
San Giovanni in Persiceto 8
Vienna 8
Crocetta 7
Totale 7.931
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 380
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 353
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity 343
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 305
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 278
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 242
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 226
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 221
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 213
CD99 Acts as an Oncosuppressor in Osteosarcoma. 201
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 197
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscape 195
Virus-like particle display of HER2 induces potent anti-cancer responses 193
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 193
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 190
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 187
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 186
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. 184
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 183
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 175
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 173
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma 170
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 169
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 169
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 168
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 167
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 166
In silico modeling and in vivo efficacy of cancer preventive vaccinations 166
Antimetastatic activity of a preventive cancer vaccine. 166
Targeting CD99 compromises the oncogenic effects of the chimera EWS-FLI1 by inducing re-expression of zyxin and inhibition of Gli1 activity 165
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 163
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 163
Immunoprevention and immunotherapy of mammary carcinoma 161
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 161
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer 159
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 157
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 154
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 153
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 153
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality 151
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 151
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 150
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 149
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 149
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 148
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 148
Immunological prevention of a multigene cancer syndrome 147
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research 146
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 144
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. 143
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 141
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 141
TRAF6 regulates proliferation and differentiation of skeletal myoblasts 141
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 140
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 136
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 135
APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. 134
NVE-BEZ235 as a new therapeutic option for sarcomas. 133
Molecular and cellular biology of rhabdomyosarcoma 129
Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma 128
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 128
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 128
Vaccines and other immunological approaches for cancer immunoprevention 125
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 125
RIP2 regulates growth and differentiation of normal myoblasts and of rhabdomyosarcoma cells. 116
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma 115
Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma. 111
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 109
Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells 107
Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy. 105
IL-1 Family Members in Bone Sarcomas 74
Genomic profiling of a collection of patient-derived xenografts and cell lines identified ixabepilone as an active drug against chemo-resistant osteosarcoma 53
Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts 45
Totale 12.073
Categoria #
all - tutte 33.072
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.072


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021867 0 0 0 0 0 48 43 132 130 57 49 408
2021/20221.471 122 48 104 58 123 86 39 107 81 128 337 238
2022/20231.923 183 227 111 277 123 132 67 104 278 73 176 172
2023/2024630 28 80 28 47 38 63 36 221 17 32 13 27
2024/20251.926 135 246 154 114 282 115 132 88 20 156 98 386
2025/20262.542 762 439 345 327 489 180 0 0 0 0 0 0
Totale 12.073